bioMérieux Brand Guidelines: Alain Mérieux’s 1963 Lyon Firm, VITEK & BioFire

A family name from Lyon.

bioMérieux dates its creation to 1963, and to a family name with older roots in Lyon. The company says its roots go back to the 19th century and to Marcel Mérieux, a student of Louis Pasteur, and the Institut Mérieux that grew from his work remains the family’s holding company today.

In 1963 Alain Mérieux, Marcel Mérieux’s grandson, set up BD Mérieux, owned in equal shares by the Institut Mérieux and the American company Becton Dickinson, French Wikipedia says. In 1974 he took control of the business, which then became bioMérieux; the company gives the same two dates in its own history. The name has kept its distinctive form ever since: a lower-case “bio” joined to the family name, accent included.

The early products were the everyday materials of the microbiology laboratory. The company says it began producing and selling ready-to-use culture media in Petri dishes in 1972, and in 1974 launched the Slidex Meningitis kit, which it describes as its first test to identify an infectious disease without first growing a culture. Its headquarters are at Marcy-l’Étoile, close to Lyon, where both English and French Wikipedia place it.

API, VITEK and BioFire.

bioMérieux grew through acquisitions that each brought a recognisable product name. In 1986, by the company’s dating, it bought API Systems of La Balme in France, a specialist in bacterial identification and antibiotic susceptibility testing; English Wikipedia gives the year as 1987. In 1988 it bought Vitek Systems, based in St. Louis, Missouri, French Wikipedia says. VITEK remains a bioMérieux name for automated identification and susceptibility systems, from the VITEK 2 Compact launched in 2004 to the VITEK MS PRIME mass-spectrometry system that the company says received FDA clearance in 2022. In 2001 it bought Organon Teknika, the in-vitro diagnostics business of Akzo Nobel.

Molecular biology arrived in stages. The company says it acquired the BOOM extraction and NASBA amplification technologies in 1990 and launched the NucliSENS EasyQ platform for real-time molecular detection in 2002. In 2006 it opened the Centre Christophe Mérieux in Grenoble, devoted to molecular biology and micro-systems, and in 2011 it bought Argene, based at Verniolle in the Ariège, a unit that French Wikipedia says drew wide media attention in March 2020 for its capacity to produce Covid-19 tests. In 2014 it launched VIRTUO, a CE-marked blood culture system, the company says.

The next step came from Utah. bioMérieux agreed in September 2013 to buy BioFire Diagnostics of Salt Lake City, formerly Idaho Technology, and it completed the purchase in January 2014, Clinical Lab Products reported on 21 January 2014. BioFire had developed FilmArray, a multiplex PCR system that brings sample preparation, amplification, detection and analysis into one instrument, with each panel testing for more than twenty pathogens at once, the magazine said; it described the method as a “syndromic approach”, looking for the likely causes of a set of symptoms with a single reagent. bioMérieux has since carried the BioFire name across a family of systems, including the BIOFIRE SPOTFIRE system, which the company says received FDA clearance and a CLIA waiver in 2023 for use at the point of care.

The company describes its work in two halves, clinical and industrial: tests for hospital laboratories, and tests that food and pharmaceutical manufacturers use to check their products for micro-organisms. It says three quarters of its research and development, and 80 percent of its product portfolio, focus on antimicrobial resistance.

How a diagnostics brand presents itself.

In vitro diagnostics is a business most people meet only at second hand, through a blood sample sent away or a result read back by a doctor. The companies behind those results make analysers, the reagents that run on them and the software that ties them together, and they sell mainly to hospital laboratories, independent labs and clinics rather than to the public.

That shapes how they look. The typical product photograph shows a white or pale grey bench analyser in a clean laboratory, sometimes linked to others in a line of automation, with sample tubes standing in racks and a touchscreen at the front. Smaller formats appear too: single-use cartridges for point-of-care machines, test strips and cassettes for rapid tests, pipettes and reagent packs. Blue and white palettes are common across the sector, along with plain sans serif type and diagrams of the laboratory workflow, and some makers have had their instruments judged on design: Sysmex’s clinical laboratory system was among the Good Design Gold Award winners in Japan in 2011.

The trade meets at a few large events. MEDICA in Düsseldorf gathers medical technology makers, and the annual meeting of ADLM, the Association for Diagnostics & Laboratory Medicine, formerly the American Association for Clinical Chemistry, brings laboratory companies together in the United States. Some of these groups grew by acquisition, so a single corporate name often sits above product names that began with other companies.

This guide sets out what can be checked about each brand: who founded it, who owns it, where its products are made and what it says about its own identity, and it marks clearly what rests only on the company’s own word. No diagnostic or clinical claims are made for any product.

Still controlled by the Mérieux family.

bioMérieux was listed on the Paris stock exchange in 2004, but it has stayed a family-controlled company. French Wikipedia says the board of the Institut Mérieux approved in May 2026 the purchase of a further one percent of bioMérieux, taking its stake to nearly 60 percent, and that in July 2022 Exor, the Agnelli family’s holding company, took 10 percent of the Institut Mérieux itself. Alain Mérieux handed the chief executive role to Jean-Luc Bélingard in 2011; his son Alexandre Mérieux became chief executive in 2014 and chairman and chief executive in December 2017, French Wikipedia says. In 2023 the roles were split, with Alexandre Mérieux as executive president and Pierre Boulud as chief executive, the company says.

Acquisitions have continued in software, sequencing and small instruments. The company lists LUMED, a clinical decision-support software company, in 2024; SpinChip of Norway and Day Zero Diagnostics of the United States in 2025; and Accellix, a flow-cytometry company, in 2026. In 2023 it made a strategic investment in Oxford Nanopore. English Wikipedia says it is present in 44 countries and serves more than 160 through distributors; French Wikipedia gives 46 countries with subsidiaries.

For a design guide, bioMérieux shows how a family name, a lower-case prefix and a set of product names inherited through acquisition can sit together in one house. Compare Roche, another European diagnostics name, and Sysmex, with which bioMérieux formed a commercial joint venture in 2008, French Wikipedia says. For this guide we use a deep blue, ink and an agar cream with a culture red, set with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep bioMérieux’s identity on hand — save it to a board in the Made Good inspiration library.